• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hematopoietic stem cell transplantation activity in China 2020-2021 during the SARS-CoV-2 pandemic: a report from the Chinese Blood and Marrow Transplantation Registry Group.
Hematopoietic stem cell transplantation (HSCT) is an established therapy for many malignant and nonmalignant hematologic diseases as well as other life-threatening diseases1, 2 3, 4. The Chinese Blood and Marrow Transplantation Registry Group (CBMTRG) was established in 2007 and collects transplant data in China every 6 months. The analysis using data from the CBMTRG illustrated a steady increase in the annual numbers of HSCTs since 20085, 6. Coronavirus disease 2019 (COVID-19), a severe respiratory illness caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in the beginning of 2020 an...
Source: Biology of Blood and Marrow Transplantation - November 16, 2022 Category: Hematology Authors: Lan-Ping Xu, Dao-Pei Lu, De-Pei Wu, Er-Lie Jiang, Dai-Hong Liu, He Huang, Zi-Min Sun, Nai-Nong Li, Qi-Fa Liu, Xi Zhang, Yong-Rong Lai, Yong-Ping Song, Xian-Min Song, Si-Xi Liu, Yi-Cheng Zhang, Cheng-Juan Luo, Ling-Hui Xia, Ting Niu, Yu Yu, Xiao-Hui Zhang, Source Type: research

Safety and Tolerability of SARS-CoV-2 Emergency-Use Authorized Vaccines Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) is a novel coronavirus emerging from Wuhan, China that can cause severe respiratory illness and a myriad of other complications that is now known as COVID-19. This disease was declared a pandemic by World Health Organization in March 2020 and has affected hundreds of millions of people worldwide1. COVID-19  clinical presentations can vary greatly between patients and those who are at highest risk for severe illness leading to hospitalization and/or death include older age, obesity, diabetes, and immunocompromised state, amongst other conditions2.
Source: Biology of Blood and Marrow Transplantation - July 15, 2021 Category: Hematology Authors: Haris Ali, Dat Ngo, Ahmed Aribi, Shukaib Arslan, Sanjeet Dadwal, Guido Marcucci, Ryotaro Nakamura, Stephen J. Forman, Jason Chen, Monzr M. Al Malki Source Type: research

Impact of SARS-CoV-2 in hematopoietic stem cell transplant and CAR-T cell therapy recipients
Coronavirus disease 2019 (COVID-19), a severe respiratory illness caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization (WHO) on March 11th 20201,2. As of May 2021, 175 million cases of SARS-CoV-2 have been reported worldwide, with over 30 million being in the United States (US)3. The COVID-19 pandemic has so far claimed nearly 3.8 million lives with over 0.5 million from the US alone and hence has had a significant impact on the healthcare systems across the globe3.
Source: Biology of Blood and Marrow Transplantation - July 10, 2021 Category: Hematology Authors: Muhammad Umair Mushtaq, Moazzam Shahzad, Sibgha Gull Chaudhary, Mary Luder, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Ramesh Balusu, Shaun DeJarnette, Clint Divine, Robert Kribs, Leyla Shune, Anurag K. Singh, Siddhartha Ganguly, Sunil H. Abhyankar Source Type: research

Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients
Coronavirus disease 2019 (COVID-19), a severe respiratory illness caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared a pandemic by the World Health Organization (WHO) on March 11, 2020 [1,2]. As of May 2021, 175 million cases of SARS-CoV-2 have been reported worldwide, including>30 million in the United States [3]. So far, the COVID-19 pandemic has claimed nearly 3.8 million lives worldwide, including>600,000 from the United States alone, and thus has had a significant impact on the healthcare systems across the globe [3].
Source: Biology of Blood and Marrow Transplantation - July 10, 2021 Category: Hematology Authors: Muhammad Umair Mushtaq, Moazzam Shahzad, Sibgha Gull Chaudhary, Mary Luder, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Ramesh Balusu, Shaun DeJarnette, Clint Divine, Robert Kribs, Leyla Shune, Anurag K. Singh, Siddhartha Ganguly, Sunil H. Abhyankar Source Type: research

COVID-19-related myocarditis post-heart transplantation
We present a case of COVID-19-related post-myocarditis state on MRI late after initial infection in a HT recipient.
Source: International Journal of Infectious Diseases - April 13, 2021 Category: Infectious Diseases Authors: Stefan Roest, Jasper J. Brugts, Jeroen J.A. van Kampen, Jan H. von der Th üsen, Alina A. Constantinescu, Kadir Caliskan, Alexander Hirsch, Olivier C. Manintveld Source Type: research

Fight Aging! Newsletter, February 22nd 2021
In conclusion, long term LRIC could decrease blood pressure and ameliorate vascular remodeling via inflammation regulation. The Damage of a Heart Attack Causes the Immune System to Overreact https://www.fightaging.org/archives/2021/02/the-damage-of-a-heart-attack-causes-the-immune-system-to-overreact/ Researchers here note a mechanism that causes T cells of the adaptive immune system to spur chronic inflammation and tissue damage following a heart attack. As the researchers note, not all inflammation is the same. Some is maladaptive, and this is particularly the case in older individuals. The aged immune...
Source: Fight Aging! - February 21, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Application of Plastic Sheet Barrier and Video Intubating Stylet to Protect Tracheal Intubators During Coronavirus Disease 2019 Pandemic: A Taiwan Experience
Cell Transplant. 2021 Jan-Dec;30:963689720987527. doi: 10.1177/0963689720987527.ABSTRACTSince its outbreak in China, the Coronavirus disease 2019 (COVID-19) pandemic has caused worldwide disaster. Globally, there have been 71,581,532 confirmed cases of COVID-19, including 1,618,374 deaths, reported to World Health Organization (data retrieved on December 16, 2020). Currently, no treatment modalities for COVID-19 (e.g., vaccines or antiviral drugs) with confirmed efficacy and safety are available. Although the possibilities and relevant challenges of some alternatives (e.g., use of stem cells as immunomodulators) have been ...
Source: Cell Transplantation - January 11, 2021 Category: Cytology Authors: Hsiang-Ning Luk Yao-Lin Yang Ching-Hsuan Huang I-Min Su Phil B Tsai Source Type: research

Application of Plastic Sheet Barrier and Video Intubating Stylet to Protect Tracheal Intubators During Coronavirus Disease 2019 Pandemic: A Taiwan Experience.
Abstract Since its outbreak in China, the Coronavirus disease 2019 (COVID-19) pandemic has caused worldwide disaster. Globally, there have been 71,581,532 confirmed cases of COVID-19, including 1,618,374 deaths, reported to World Health Organization (data retrieved on December 16, 2020). Currently, no treatment modalities for COVID-19 (e.g., vaccines or antiviral drugs) with confirmed efficacy and safety are available. Although the possibilities and relevant challenges of some alternatives (e.g., use of stem cells as immunomodulators) have been proposed, the personal protective equipment is still the only way to p...
Source: Cell Transplantation - January 1, 2021 Category: Cytology Authors: Luk HN, Yang YL, Huang CH, Su IM, Tsai PB Tags: Cell Transplant Source Type: research

Addressing the importance of Stem cell-based therapy: a Perspective in the treatment of COVID-19'.
Abstract Severe acute respiratory syndrome-associated corona virus 2 (SARS-CoV-2), is an extremely pathogenic virus belonging to the family of Coronaviridae. First identified in Wuhan China in December 2019 after an epidemiological investigation of an emerging cluster of pneumonia of unknown etiology, SARS-CoV-2 was declared the cause of a pandemic on March 11 by the World Health Organization (WHO) pointing to the over 118000 cases of Coronavirus disease 2019 (COVID- 19) in over 110 countries. Despite the promising results of drug repositioning studies in the treatment of COVID-19, the evidence of their safety and...
Source: Current Molecular Medicine - November 17, 2020 Category: Molecular Biology Authors: Ibrahim C, Semaan H, El-Sabban M, Najjar F, Hamade A Tags: Curr Mol Med Source Type: research

Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic.
Abstract Coronaviruses are pleomorphic, enveloped, or spherical viruses, which have a size ranging from 80 to 120 nm. These viruses act on receptors that cause the triggering of fusion. Coronaviruses were first described after cultivation from patients with common colds by Tyrell and Bynoe in 1966. There are various subtypes of coronavirus, 7 out of these can cause infection in human beings. The Alpha subtype is responsible for mild infection showing symptoms or infection without any prevailing symptoms. On the other hand, the beta subtype is responsible for very serious diseases leading to fatality. The lineage...
Source: European Journal of Pharmacology - October 13, 2020 Category: Drugs & Pharmacology Authors: Bhandari R, Khanna G, Kuhad A Tags: Eur J Pharmacol Source Type: research

Viral Outbreaks Are Here to Stay. This is How Humans Will Fight Back
The year of the rat is off to an ominous start. “We just stay home and don’t go out,” says Mr. Dong. The 33-year-old researcher, who provided only one name, has no other options. He, his wife and their 3-month-old daughter live in Wuhan, the epicenter of an unfolding global health crisis. They’re treating the forced time at home as a holiday, though he says, “this is different than any of them before.” Families like his huddle in their homes, fearful that if they venture out, they will get sick. Since the first cases of a previously unknown pneumonia-like illness emerged in December, Wuh...
Source: TIME: Health - January 30, 2020 Category: Consumer Health News Authors: Alice Park and Charlie Campbell Tags: Uncategorized Source Type: news

Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid
In this study, we evaluated ATA as a potential antiviral drug against ZIKV replication. The antiviral activity of ATA against ZIKV replication in vitro showed median inhibitory concentrations (IC50) of 13.87 ± 1.09 μM and 33.33 ± 1.13 μM in Vero and A549 cells, respectively; without showing any cytotoxic effect in both cell lines (median cytotoxic concentration (CC50)> 1,000 μM). Moreover, ATA protected both cell types from ZIKV-induced cytopathic effect (CPE) and apoptosis in a time- and concentration-dependent manner. In addition, pre-treatment of Vero cells with ATA for up to 72 h also...
Source: Frontiers in Microbiology - April 11, 2019 Category: Microbiology Source Type: research